RAPT Therapeutics (NASDAQ:RAPT) Shares Scheduled to Reverse Split on Tuesday, June 17th

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) shares are set to reverse split on the morning of Tuesday, June 17th. The 1-8 reverse split was announced on Friday, June 13th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 16th.

RAPT Therapeutics Stock Performance

NASDAQ:RAPT traded down $0.01 during mid-day trading on Monday, reaching $1.03. 902,165 shares of the company's stock were exchanged, compared to its average volume of 1,286,899. RAPT Therapeutics has a one year low of $0.71 and a one year high of $3.83. The firm has a market capitalization of $136.26 million, a PE ratio of -0.37 and a beta of -0.11. The business's fifty day simple moving average is $0.93 and its two-hundred day simple moving average is $1.12.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. As a group, equities research analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RAPT. Wall Street Zen upgraded shares of RAPT Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright upgraded shares of RAPT Therapeutics to a "strong-buy" rating and set a $6.00 price objective on the stock in a research note on Thursday, May 22nd. Finally, UBS Group reduced their price objective on shares of RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $3.00.

Institutional Investors Weigh In On RAPT Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Checkpoint Capital L.P. acquired a new stake in shares of RAPT Therapeutics in the 1st quarter valued at approximately $134,000. AQR Capital Management LLC acquired a new stake in shares of RAPT Therapeutics in the 1st quarter valued at approximately $188,000. ADAR1 Capital Management LLC boosted its stake in shares of RAPT Therapeutics by 408.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company's stock valued at $7,284,000 after purchasing an additional 4,796,455 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of RAPT Therapeutics by 303.1% in the 1st quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company's stock valued at $6,116,000 after purchasing an additional 3,769,414 shares in the last quarter. Finally, Comerica Bank boosted its stake in shares of RAPT Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after purchasing an additional 31,287 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.